Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy

American Journal of Pathology

Volumn 178, Issue 3, 2011, Pages 1287-1297

  Pistilli, Emidio E ^a   Bogdanovich, Sasha ^a,c   Goncalves, Marcus D ^a   Ahima, Rexford S ^a   Lachey, Jennifer ^b   Seehra, Jasbir ^b   Khurana, Tejvir S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Acceleron Pharma   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR 2 FC RECEPTOR IIB HYBRID PROTEIN; CREATINE KINASE; FC RECEPTOR IIB; IMMUNOGLOBULIN G; RAP 031; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DUCHENNE MUSCULAR DYSTROPHY; EX VIVO STUDY; EXTENSOR DIGITORUM LONGUS MUSCLE; GENE TARGETING; MALE; MOUSE; MUSCLE FUNCTION; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

EID: 79952764909     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.11.071     Document Type: Article

References (59)

1. Adams RD, Victor M: Principles of Neurology, ed 4. New York, McGraw-Hill, 1989, pp 1117-1132
2. Hoffman EP, Brown RH Jr, Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51:919-928
3. Bogdanovich S, Perkins KJ, Krag TO, Khurana TS: Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. J Mol Med 2004, 82:102-115 (Pubitemid 38299709)
4. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL: Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 1993, 90:3710-3714 (Pubitemid 23111437)
5. Engel AG, Ozawa E: Dystrophinopathies. Myology, vol 2, ed 3, ch 34. Edited by AG Engel, C Franzini-Armstrong. New York, McGraw-Hill, 2004, pp 961-1026
6. Ames WA, Hayes JA, Crawford MW: The role of corticosteroids in Duchenne muscular dystrophy: a review for the anesthetist. Paediatr Anaesth 2005, 15:3-8 (Pubitemid 40188785)
7. Angelini C: The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve 2007, 36:424-435
8. Bonifati MD, Ruzza G, Bonometto P, Berardinelli A, Gorni K, Orcesi S, Lanzi G, Angelini C: A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000, 23:1344-1347
9. + stem cells in Duchenne muscle patients. Cell Transplant 2007, 16:563-577
10. Peltz SW, Welch EM, Jacobson A, Trotta CR, Naryshkin N, Sweeney HL, Bedwell DM: Nonsense suppression activity of PTC124 (ataluren). Proc Natl Acad Sci USA 2009, 106(25):E64; author reply E65
11. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL: PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007, 447:87-91 (Pubitemid 46685839)
12. Skuk D, Goulet M, Roy B, Chapdelaine P, Bouchard JP, Roy R, Dugré FJ, Sylvain M, Lachance JG, Deschênes L, Senay H, Tremblay JP: Dystrophin expression in muscles of Duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J Neuropathol Exp Neurol 2006, 65:371-386 (Pubitemid 44264834)
13. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P, Garralda ME, Rutherford M, McCulley C, Popplewell L, Graham IR, Dickson G, Wood MJ, Wells DJ, Wilton SD, Kole R, Straub V, Bushby K, Sewry C, Morgan JE, Muntoni F: Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009, 8:918-928
14. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooi AJ, Goemans NM, de Kimpe SJ, Ekhart PF, Venneker EH, Platenburg GJ, Verschuuren JJ, van Ommen GJ: Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007, 357:2677-2686
15. Odom GL, Gregorevic P, Chamberlain JS: Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta 2007, 1772:243-262 (Pubitemid 46123917)
16. Banks GB, Chamberlain JS: The value of mammalian models for Duchenne muscular dystrophy in developing therapeutic strategies. Curr Top Dev Biol 2008, 84:431-453
17. Gehrig SM, Ryall JG, Schertzer JD, Lynch GS: Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage. Exp Physiol 2008, 93:1190-1198
18. Schertzer JD, Gehrig SM, Ryall JG, Lynch GS: Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice. Am J Pathol 2007, 171:1180-1188 (Pubitemid 47582892)
19. Schertzer JD, van der Poel C, Shavlakadze T, Grounds MD, Lynch GS: Muscle-specific overexpression of IGF-I improves E-C coupling in skeletal muscle fibers from dystrophic mdx mice. Am J Physiol Cell Physiol 2008, 294:C161-C168
20. Harcourt LJ, Holmes AG, Gregorevic P, Schertzer JD, Stupka N, Plant DR, Lynch GS: Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. Am J Pathol 2005, 166:1131-1141
21. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS: Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002, 420:418-421 (Pubitemid 35415652)
22. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS: Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 2005, 19:543-549 (Pubitemid 40471245)
23. Wagner KR, McPherron AC, Winik N, Lee SJ: Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 2002, 52:832-836 (Pubitemid 35403195)
24. McPherron AC, Lee SJ: Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 1997, 94:12457-12461 (Pubitemid 27492550)
25. Amthor H, Macharia R, Navarrete R, Schuelke M, Brown SC, Otto A, Voit T, Muntoni F, Vrbóva G, Partridge T, Zammit P, Bunger L, Patel K: Lack of myostatin results in excessive muscle growth but impaired force generation [Erratum appeared in Proc Natl Acad Sci USA 2007, 104:4240]. Proc Natl Acad Sci USA 2007, 104:1835-1840
26. Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker HG, Ostrander EA: A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 2007, 3:e79
27. Shelton GD, Engvall E: Gross muscle hypertrophy in whippet dogs is caused by a mutation in the myostatin gene. Neuromuscul Disord 2007, 17:721-722 (Pubitemid 47362683)
28. Schuelke M, Wagner KR, Stolz LE, Hübner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ: Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004, 350:2682-2688 (Pubitemid 38788003)
29. Fedoruk MN, Rupert JL: Myostatin inhibition: a potential performance enhancement strategy? Scand J Med Sci Sports 2008, 18:123-131
30. Whittemore LA, Song K, Li X, Aghajanian J, Davies M, Girgenrath S, Hill JJ, Jalenak M, Kelley P, Knight A, Maylor R, O'Hara D, Pearson A, Quazi A, Ryerson S, Tan XY, Tomkinson KN, Veldman GM, Widom A, Wright JF, Wudyka S, Zhao L, Wolfman NM: Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 2003, 300:965-971
31. Magee TR, Artaza JN, Ferrini MG, Vernet D, Zuniga FI, Cantini L, Reisz-Porszasz S, Rajfer J, Gonzalez-Cadavid NF: Myostatin short interfering hairpin RNA gene transfer increases skeletal muscle mass. J Gene Med 2006, 8:1171-1181 (Pubitemid 44480408)
32. Bartoli M, Poupiot J, Vulin A, Fougerousse F, Arandel L, Daniele N, Roudaut C, Noulet F, Garcia L, Danos O, Richard I: AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene Ther 2007, 14:733-740 (Pubitemid 46585654)
33. de Caestecker M: The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev 2004, 15:1-11
34. Lee SJ, Reed LA, Davies MV, Girgenrath S, Goad ME, Tomkinson KN, Wright JF, Barker C, Ehrmantraut G, Holmstrom J, Trowell B, Gertz B, Jiang MS, Sebald SM, Matzuk M, Li E, Liang LF, Quattlebaum E, Stotish RL, Wolfman NM: Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 2005, 102:18117-18122 (Pubitemid 41798511)
35. Qiu P, Feng XH, Li L: Interaction of Smad3 and SRF-associated complex mediates TGF-beta1 signals to regulate SM22 transcription during myofibroblast differentiation. J Mol Cell Cardiol 2003, 35:1407-1420 (Pubitemid 37491184)
36. Goncalves MD, Pistilli EE, Balduzzi A, Birnbaum MJ, Lachey J, Khurana TS, Ahima RS: Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition. PLoS One 2010, 5:e12707
37. Chen S, Kulik M, Lechleider RJ: Smad proteins regulate transcriptional induction of the SM22alpha gene by TGF-beta. Nucleic Acids Res 2003, 31:1302-1310 (Pubitemid 36284971)
38. Amirouche A, Durieux AC, Banzet S, Koulmann N, Bonnefoy R, Mouret C, Bigard X, Peinnequin A, Freyssenet D: Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle. Endocrinology 2009, 150:286-294
39. Wong T, Hildebrandt MA, Thrasher SM, Appleton JA, Ahima RS, Wu GD: Divergent metabolic adaptations to intestinal parasitic nematode infection in mice susceptible or resistant to obesity. Gastroenterology 2007, 133:1979-1988 (Pubitemid 350180809)
40. Brooks SV, Faulkner JA: Contractile properties of skeletal muscles from young, adult and aged mice. J Physiol 1988, 404:71-82
41. Lynch GS, Hinkle RT, Chamberlain JS, Brooks SV, Faulkner JA: Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J Physiol 2001, 535:591-600 (Pubitemid 32825693)
42. Gargioli C, Coletta M, De Grandis F, Cannata SM, Cossu G: PlGF-MMP-9-expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle. Nat Med 2008, 14:973-978
43. Pistilli EE, Siu PM, Alway SE: Interleukin-15 responses to aging and unloading-induced skeletal muscle atrophy. Am J Physiol Cell Physiol 2007, 292:C1298-C1304 (Pubitemid 46631721)
44. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT, Kelly AM: The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991, 352:536-539
45. Coulton GR, Morgan JE, Partridge TA, Sloper JC: The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation. Neuropathol Appl Neurobiol 1988, 14:53-70
46. Tidball JG, Wehling-Henricks M: Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events. Pediatr Res 2004, 56:831-841 (Pubitemid 39552762)
47. Danièle N, Richard I, Bartoli M: Ins and outs of therapy in limb girdle muscular dystrophies. Int J Biochem Cell Biol 2007, 39:1608-1624 (Pubitemid 47090212)
48. Nagaraju K, Willmann R; TREAT-NMD Network and the Wellstone Muscular Dystrophy Cooperative Research Network: Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC. October 27th-28th 2007 and Zurich, June 30th-July 1st 2008. Neuromuscul Disord 2009, 19:502-506
49. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, Van Der Meulen JH, Cha HJ, Pistilli EE, Partridge TA, Hoffman EP, Nagaraju K: Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 2009, 39:591-602
50. Morrison BM, Lachey JL, Warsing LC, Ting BL, Pullen AE, Underwood KW, Kumar R, Sako D, Grinberg A, Wong V, Colantuoni E, Seehra JS, Wagner KR: A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 2009, 217:258-268
51. Akpan I, Goncalves MD, Dhir R, Yin X, Pistilli EE, Bogdanovich S, Khurana TS, Ucran J, Lachey J, Ahima RS: The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond) 2009, 33:1265-1273
52. Pistilli EE, Bogdanovich S, Mosqueira M, Lachey J, Seehra J, Khurana TS: Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction. Am J Physiol Regul Integr Comp Physiol 2010, 298:R96-R103
53. Sako D, Grinberg AV, Liu J, Davies MV, Castonguay R, Maniatis S, Andreucci AJ, Pobre EG, Tomkinson KN, Monnell TE, Ucran JA, Martinez-Hackert E, Pearsall RS, Underwood KW, Seehra J, Kumar R: Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J Biol Chem 2010, 285:21037-21048
54. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, Lavallie ER, Mendell JR: A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008, 63:561-571
55. Cadena SM, Tomkinson KN, Monnell TE, Spaits MS, Kumar R, Underwood KW, Pearsall RS, Lachey JL: Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol 2010, 109:635-642
56. Hurley BF, Redmond RA, Pratley RE, Treuth MS, Rogers MA, Goldberg AP: Effects of strength training on muscle hypertrophy and muscle cell disruption in older men. Int J Sports Med 1995, 16:378-384
57. Vincent HK, Vincent KR: The effect of training status on the serum creatine kinase response, soreness and muscle function following resistance exercise. Int J Sports Med 1997, 18:431-437 (Pubitemid 27434471)
58. Li ZB, Kollias HD, Wagner KR: Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem 2008, 283:19371-19378
59. Murphy KT, Ryall JG, Snell SM, Nair L, Koopman R, Krasney PA, Ibebunjo C, Holden KS, Loria PM, Salatto CT, Lynch GS: Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice. Am J Pathol 2010, 176:2425-2434